Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558929 | 0.76 | LRRK2 (0.45) | MAP3K12MAPK1PIK3CAMTORLRRK2 | |
| SCHEMBL23181497 | 0.73 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL29419405 | 0.72 | PIK3CA (0.48) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL14764312 | 0.72 | PIK3CA (0.48) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL13724214 | 0.70 | NOTUM (0.38) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL19313503 | 0.70 | NOTUM (0.38) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL23025135 | 0.70 | RET (0.38) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL23181524 | 0.70 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL5559958 | 0.69 | PIK3CD (0.43) | MAP3K12MAPK1KDM5BDHFRPIK3CA | |
| SCHEMBL30367774 | 0.68 | CYP1A2 (0.44) | KDM5BPIK3CAPIK3CDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | MAP3K12 3414/4885MAPK1 3067/4885KDM5B 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.